MYO News and Press, Myomo Inc. From 03/24/21

Myomo develops, manufactures, and sells a wearable medical device for stroke patients that lost control or strength in their arms. Myomo's recent quarter and future growth prospects look bright in part because they received the Medicare Certification. They are overhauling their ma...

Myomo, Inc. (MYO) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Kim Golodetz - LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Kyle Bauser - Colliers Securities Jim Sidoti...

Myomo (MYO): Q4 Non-GAAP EPS of -$0.37 beats by $0.18; GAAP EPS of -$0.36 beats by $0.13.Revenue of $3.79M (+149.3% Y/Y) beats by $0.44M.101 units were delivered to patients including 97 recognized as revenue, a 126% increase.Backlog, which represents insurance authorizations received but not...

Record Q4 2020 revenue of $3.8 million up 149% over prior year Full year 2020 revenue of $7.6 million up 98% vs. 2019 Q4 gross margin of 73% up 100 basis points over prior year Q4 cash used in operations of $1.2 million lowest since June 2017 IPO Confer...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Myomo’s...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial re...

Follows approval by several other major German providers Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders a...

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at ...

Myomo (MYO) surged 27% in premarket trade after it inked a joint venture agreement with Beijing Ryzur Medical Investment for manufacturing and selling the company's current and future products in greater China, including Hong Kong, Macau and Taiwan.Majo...

Edesa Biotech (EDSA) +97% on regulatory nod for sub set of phase2/3 EB05 COVID-19 study.Koss Corporation (KOSS) +84%.Phunware (PHUN) +65%.Vertex Energy (VTNR) +52%.Myomo (MYO) +33% on JV to manufacture and sell the company’s products in China.AIkido Pharma (AIKI) +2...